ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

Now Available: Top 10 Stocks for 2010

These powerful long-term stocks for 2010 have just been announced. Our top picks for 2009 generated a +34.1% return. Don’t miss out. Learn more now.

Quote:

Search for Ticker

Free Membership

Search:

GETA: Genta New - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

GENTA NEW (OTCBB)
GETA	0.11	N/A	(N/A%)	Vol. 2,601,632	15:56 ET

Genta Incorporated is a biopharmaceutical company with a product portfolio focused on anticancer therapy, including its Anticode platform technology, as well as other important anticancer products. The company's lead compound, G3139, has received ``Fast Track'' designation from the Food and Drug Administration and has entered Phase 3 trials in patients with advanced melanoma. Genta aims to become a direct marketer of its drugs in the United States. (PRESS RELEASE)

General Information

GENTA INC

200 Connell Drive Berkeley Heights, NJ 07922 Phone: 908-286-9800 Fax: 908-464-1701 Web: www.genta.com Email: info@genta.com

Industry	MED-BIOMED/GENE
Sector:	Medical

Fiscal Year End	December
Last Reported Quarter	12/31/09
Next EPS Date	N/A

Price and Volume Information

Zacks Rank
Yesterday's Close	0.11
52 Week High	1.33
52 Week Low	0.07
Beta	-1.14
20 Day Moving Average	4,276,716.00
Target Price Consensus	N/A

% Price Change
4 Week	20.00
12 Week	-44.62
YTD	24.14

% Price Change Relative to S&P 500
4 Week	29.09
12 Week	-42.38
YTD	32.24

Share Information
Shares Outstanding (millions)	191.81
Market Capitalization (millions)	20.72
Short Ratio	8.23
Last Split Date	07/13/2009

Dividend Information
Dividend Yield	0.00%
Annual Dividend	$0.00
Payout Ratio	0.00
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	N/A
Current Year EPS Consensus Estimate	N/A
Estimated Long-Term EPS Growth Rate	N/A
Next EPS Report Date	N/A

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	N/A
30 Days Ago	N/A
60 Days Ago	N/A
90 Days Ago	N/A

Fundamental Ratios

P/E
Current FY Estimate:	-
Trailing 12 Months:	-
PEG Ratio	-

EPS Growth
vs. Previous Year	70.00%
vs. Previous Quarter	76.19%

Sales Growth
vs. Previous Year	-57.39%
vs. Previous Quarter:	-28.99%

Price Ratios
Price/Book	2.71
Price/Cash Flow	0.01
Price / Sales	-

ROE
12/31/09	-
09/30/09	-
06/30/09	-

ROA
12/31/09	-
09/30/09	-316.63
06/30/09	-184.60

Current Ratio
12/31/09	-
09/30/09	0.67
06/30/09	0.12

Quick Ratio
12/31/09	-
09/30/09	0.66
06/30/09	0.11

Operating Margin
12/31/09	-
09/30/09	-
06/30/09	-

Net Margin
12/31/09	-
09/30/09	-26,099.98
06/30/09	75,634.16

Pre-Tax Margin
12/31/09	-
09/30/09	-26,099.98
06/30/09	75,634.16

Book Value
12/31/09	-
09/30/09	0.04
06/30/09	-0.06

Inventory Turnover
12/31/09	-
09/30/09	0.45
06/30/09	0.50

Debt-to-Equity
12/31/09	-
09/30/09	0.39
06/30/09	-0.11

Debt to Capital
12/31/09	-
09/30/09	28.04
06/30/09	-


About Zacks \| Advertise \| Affiliate \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2010 Zacks Investment Research